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Thornton).Allosteric regulation of protein function occurs when the regulatory trigger, such as the binding of a
small-molecule effector or inhibitor, takes place some distance from the protein’s, or protein com-
plex’s, active site. This distance can be a few Å, or tens of Å. Many proteins are regulated in this way
and exhibit a variety of allosteric mechanisms. Here we review how analyses of experimentally
determined models of protein 3D structures, using either X-ray crystallography or NMR spectros-
copy, have revealed some of the mechanisms involved.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Regulation of protein function is crucial to all organisms. Virtu-
ally all processes in the cell need to be carefully controlled and, if
these controls fail, can lead to malfunction and disease. The control
can be exerted at various different points in a protein’s lifetime:
from regulation of gene expression, through translation into pro-
tein, via control over its level of activity, to its ﬁnal degradation
[1]. Allosteric regulation is just one of many controls on activity,
but a particularly interesting one. It entails a regulatory trigger,
such as the binding of a small molecule to a protein or protein
complex, which takes place at a site some distance from the active
site. In some cases the two sites can be tens of Å apart, so it be-
comes interesting to ask how the signal is transmitted over such
a distance.
Furthermore, allosteric triggers can increase as well as decrease
the protein’s activity. This differs from simple competitive inhibi-chemical Societies. Published by E
ype A; CAK, CDK-activating
xy-D-arbino-heptulosonate-7-
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lmer model; MWC, Monod,
g domain; PDB, Protein Data
ycerate dehydrogenase; PTS,
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ki), thornton@ebi.ac.uk (J.M.tion wherein a small-molecule inhibitor, or indeed another protein
molecule, binds to the active site and prevents the protein’s natural
substrate gaining access. It also differs in that, whereas a compet-
itive inhibitor may need to be chemically similar to the substrate in
order to compete against it, an allosteric regulator does not.
Much of the knowledge of allosteric mechanisms has come from
analyses of protein 3D structures. There are over 100 cases of allos-
terically regulated proteins for which a structural model of either
one, or both, of the active or inactive forms have been experimen-
tally determined, using either X-ray crystallography or NMR spec-
troscopy. Comparison of the structures can suggest how the
allosteric mechanism operates. Here we review some of the trig-
gers and mechanisms that have been revealed by such structural
studies.
2. Structural studies
In the 1960s, two alternative models were proposed for describ-
ing how allostery operates. Both apply to oligomeric protein
assemblies of identical protein molecules, or subunits, and assume
that each subunit is in either a relaxed state (R) or tense state (T).
The R state is more receptive to ligand binding than the T state. In
the Monod, Wyman and Changeux (MWC) model [2], also known
as the concerted or symmetry model, the subunits in each protein
assembly must either all be in the R state or all in the T state; that
is, a conformational change in one subunit causes an equivalent
change in all others. The ratio of the two types of assemblies is
determined by thermal equilibrium. However, binding of a ligand
to either state increases the equilibrium in favor of the R state, thuslsevier B.V. All rights reserved.
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This model seems to describe the mechanism that operates in
many proteins including hemoglobin [3], membrane acceptors
[4], and some enzymes [5]. In the second model, the Koshland,
Nemethy and Filmer (KNF), or sequential, model [6], the subunits
of each assembly do not all have to be in the same state. Binding
of a ligand to one subunit occurs by induced ﬁt, altering its confor-
mation from the T to the R state. This change affects the structures
of adjacent subunits, making them more receptive to ligand bind-
ing, without necessarily converting them to the R state as in MWC
model.
Both of these models describe allosteric regulation of oligomeric
assemblies. In this review we focus on examples where the alloste-
ric and active sites are distinct sites on the same protein molecule.
For the most part the examples come from 3D structural studies.
Table 1 summarizes some of the different allosteric triggers that
these studies have revealed and some of the mechanisms that have
been proposed to describe how they operate. In the examples be-
low, the structures are identiﬁed by their protein data bank
(PDB) identiﬁer which is a four-character code.
It should be noted that a 3D structure does not always provide
the full story. There are cases where there is no, or very little, struc-
tural difference between the active and inactive forms of the pro-
tein. In these cases, the allosteric mechanism cannot be
explained purely in terms of conformational change, and we dis-
cuss such cases towards the end of this review.
3. Allosteric regulation by small-molecule binding
The most common form of allosteric regulation is by the bind-
ing of small-molecule effectors or inhibitors. This is found in the
negative feedback loops of many biosynthetic pathways where
one of the products of the pathway inhibits further production of
the product by closing down an enzyme involved in one of early
steps of the pathway. Alternatively, a pathway can be activated
by the presence of a speciﬁc molecule which switches on one of
its crucial enzymes. The examples below are categorized by their
allosteric mechanism; i.e. the effect that the binding of the alloste-
ric molecule has on the protein’s active site. The methods are sche-
matically illustrated in Fig. 1.
3.1. Opening/closing of active site
The ﬁrst examples are those where the conformational change
in the protein is such that it opens up, or closes, the active site,
either enabling it to carry out its function or shutting off its activity
(Fig. 1a and d, respectively). The change can be quite dramatic,
such as a hinge motion at the boundary of two domains, or more
subtle, such as the rotation of a single side chain to control the en-
trance to the functional binding pocket.Table 1
Triggers and mechanisms of allosteric regulation.
Trigger Mechanism Effect
 Small-molecule
binding
 Protein–protein
binding
 Phosphorylation
 Modiﬁcation of
disulﬁde bonds
9>>>>>=
>>>>>;
 Open/close active site
 Change active site
conformation
 Change active site electro-
static properties
 Affect protein–protein
complex formation
 Change protein ﬂexibility
 ‘‘Population shift” in
ensemble of conformers
9>>>>>>>>=
>>>>>>>>;
Increase/decrease
in protein’s activityAn example involving a hinge motion, albeit a subtle one, is pro-
vided by phosphoglycerate dehydrogenase (PGDH). This is a NAD+-
dependent enzyme that catalyses the ﬁrst step in the biosynthesis
of L-serine. It is allosterically inhibited by the binding of the serine
end product. The protein consists of three domains: a regulatory
binding domain (RBD), which is where the allosteric inhibitor
binds, plus binding domains for substrate (SBD) and the NAD
nucleotide (NBD). The protein’s function is to oxidize 3-phospho-
glycerate into 3-phosphohydropyruvate. Comparison of the apo-
structure (PDB code 1psd) with the holo-structure, containing a
bound serine in the allosteric site (1yba), showed that the serine
binding causes a rigid-body hinge rotation of the RBD-SBD do-
mains relative to the NBD domain through about 15. As a result,
in the complete tetrameric assembly, this rotation causes a closing
off of the active site cleft and a change to the conformations of the
catalytic residues. Together, these changes effectively shut down
the enzyme [7].
The RBD belongs to a common fold called the ACT domain
which is found in a number of other allosterically controlled pro-
teins. An aspect that is common to most of these proteins is that
they are involved in amino acid biosynthesis and the allosteric
effector molecules are the end-product amino acids [8]. It is very
likely that the ACT domain is an ancient one as most of these pro-
teins are found in Bacteria and Archaea.3.2. Changes to conformation of active site
Less dramatic than the opening and closing of an active site are
minor modiﬁcations to its conformation which are nevertheless
sufﬁcient to affect the protein’s ability to bind, or properly interact
with, its substrates (Fig. 1b and e). An example here is provided by
DAHP synthase which catalyzes the ﬁrst step in the biosynthesis of
the aromatic amino acids in microorganisms and plants. The cata-
lytic reaction involves condensation of phosphoenolpyruvate (PEP)
and D-erythrose-4-phosphate (E4P) to form 3-deoxy-D-arbino-
heptulosonate-7-phosphate (DAHP). In Escherichia coli, DAHP syn-
thase (DAHPS) exists in three different isomers, each inhibited by
one of the three aromatic amino acid end products: Phe, Tyr or
Trp. The 3D structures of the apo- and holo-forms of the Phe-regu-
lated isozyme, DAHPS(Phe) are known: PDB entry 1kﬂ has the Phe
bound, while PDB entries 1qr7 and 1gg1 have no Phe. Comparison
of these structures showed that the binding of the inhibitor leaves
most of the structure unchanged apart from four, short adjacent
segments. The coordinated movement of these segments transmits
the allosteric signal to the protein’s active site which is deformed
and dramatically reduces the interaction of DAHPS with both its
substrates [9].3.3. Changes to electrostatic properties of active site
In some cases the allosteric event seems to make very little
change to the conformation of the protein’s active site, or indeed,
to the structure as a whole (more on this later). However, what lit-
tle change does take place may be sufﬁcient to alter the active site’s
electrostatic properties and hence have a signiﬁcant impact on the
protein’s function. One example where this may be the case, is gi-
ven by chorismate mutase (PDB codes 1csm and 2csm). This pro-
tein only exists in bacteria, fungi and plants and is involved in
the biosynthesis of the amino acids tyrosine and phenylalanine.
It catalyzes the conversion of dicarboxylic chorismate to prephen-
ate, which is subsequently converted to one of these two amino
acids. An alternative pathway for the dicarboxylic chorismate reac-
tant leads to the synthesis of tryptophan. So, the chorismate mu-
tase enzyme provides a branching point in the biosynthesis of all
three aromatic amino acids and is controlled by the allosteric
Fig. 1. Schematic diagram showing some of the allosteric mechanisms by which the binding of a ligand can alter the conformation of a distant active site. In all diagrams, the
protein is colored cream, the substrate molecule is blue, and allosteric regulators are green for effectors and red for inhibitors. (a–c) Show activation triggers: (a) opening of
the active site, (b) conformational change within the active site, and (c) formation of the active site by the dimerization of two protein molecules. (d–f) Show inhibitory
effects: (d) closing of the active site, (e) conformational distortion of the active site, and (f) prevention of the dimerization necessary to create an active site.
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tryptophan, and inhibited by tyrosine.
The binding of either of these regulator molecules alters the rel-
ative orientation of the catalytic and allosteric domains; binding of
the bulkier Trp pushes the domains further apart and affects the
quaternary structure of the dimer. However, the effect on the con-
formation of the catalytic site is minimal. The only signiﬁcant ef-
fect is on the conformation of the Glu23 side chain. In the active
state, this residue is buried in the active site pocket but, on binding
of the allosteric inhibitor and consequent structural changes, it
swings into the binding site. The authors suggest that the appear-
ance of this Glu in the active site causes a major change to its elec-
trostatic properties which is sufﬁcient to repel the substrate with
its negative potential [10].
3.4. Allosteric control of complex formation
There are many cases where binding of a small-molecule ligand
either enables or prevents the formation of a biologically func-
tional multimer. The binding is allosteric as it may be far from
the functional site and affects proteins that can only perform their
function when in the correct multimeric assemblage (Fig. 1c and f).
An interesting example is ATP phosphoribosyltransferase. This
catalyses the ﬁrst step of the histidine biosynthetic pathway. Each
protein chain consists of three domains: domains I and II contain
the catalytic site in the cleft between them, while domain III is
the regulatory domain. The functional quaternary structure is a di-
mer (PDB code 1nh7). The enzyme is allosterically inhibited by the
end-product histidine. When histidine binds it causes a large twist
of domain III relative to domains I and II which promotes the di-
mers to combine in groups of three, thus making hexameric assem-
blies of the protein. This grouping renders the protein inactive as
the active sites become closed on formation of these complexes
[11]. A similar mechanism operates in ribonuclease reductase [12].More interesting still, is the case of AraC. Here the allosteric reg-
ulator switches the protein from one mode of operation to another
by completely changing the way the protein dimerizes and dra-
matically affecting what it does (Fig. 2). AraC is a transcription reg-
ulator that, in E. coli, controls genes involved in the uptake and
catabolism of the sugar arabinose. It has two domains: an arabi-
nose-binding domain and a DNA-binding domain. So, when it
dimerizes, the dimer has two arabinose- and two DNA-binding do-
mains. The latter each bind to a different DNA site. With arabinose
bound (PDB code 2arc), AraC dimerizes such that the two DNA sites
to which the protein attaches itself are distantly separated (Fig. 2a
and c), creating a 210-base pair loop in the DNA and repressing
transcription of the promoters pBAD (the promoter for the arabinose
operon) and pC. If the effector molecule is absent (PDB code 2ara),
the protein dimerizes along a completely different dimerization
interface (Fig. 2b) and places the two DNA-binding domains close
together. Now the dimer attaches itself to two adjacent DNA sites
and promotes pBAD transcription instead of inhibiting it (Fig. 2d)
[13].
4. Allosteric regulation by protein binding
Proteins can also act as allosteric effectors or inhibitors for
other proteins. For example, the function of cyclin-dependent ki-
nase 2 (CDK2) is controlled, as its name suggests, by the binding
of the protein cyclin. CDK enzymes act as checkpoints in the
eukaryotic cell cycle and function by activating downstream tar-
gets by phosphorylation. Two steps are required to switch these
enzymes on. The ﬁrst is the binding of the cyclin and the second
is phosphorylation by a CDK-activating kinase (CAK). Structural
studies of CDK2 in complex with cyclin A (PDB code 1ﬁn) have
revealed how the binding of the cyclin switches CDK2 on. Firstly,
it displaces CDK2’s activation segment and makes its substrate
binding site accessible for binding ATP [14]. Secondly, it exposes
Fig. 2. Allosteric regulation by change of dimerization, as exempliﬁed by the AraC protein from Escherichia coli. (a) Secondary structure representation of the dimer formed by
the protein’s arabinose-binding domains when arabinose (shown in spaceﬁll representation) is bound (PDB code 2arc). The interface is formed by the a-helices. (b) When
arabinose is absent, the domains bind along a completely different dimerization interface (PDB code 2ara), with the twomolecules joining to form a beta barrel structure. (c) A
schematic representation of the dimer in a) (red and blue surfaces) plus the DNA-binding domains (pink and light blue surfaces, respectively) modeled in at their expected
locations at the C-terminus of each arabinose-binding domain. As a consequence of this mode of dimerization, the DNA-binding domains (DBDs) occur on either side of the
dimer and so bind to very distantly separated sites on the DNA (shown in orange). (d) When, in the absence of arabinose, the arabinose-binding domains dimerize as in (b),
the DBDs are placed side by side and attach to neighboring sites on the DNA. In (c) transcription of the regulated gene is repressed, and in (d) it is promoted.
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by CAK, forms the CDK2’s peptide binding site and thus activates
the enzyme [15].
A contrary example, of a protein acting as an allosteric inhibitor,
is phosphocarrier protein IIIGlc. This protein belongs to the bacterial
phosphotransferase system (PTS) which acts as a sugar transport
pathway. When there are ample PTS sugars available, IIIGlc be-
comes unphosphorylated and then inhibits enzymes involved in
uptake and metabolism of non-PTS carbon sources. When PTS sug-
ars become scarce, IIIGlc becomes phosphorylated and abandons its
inhibitory function. One of the proteins it operates on is glycerol ki-
nase (GK). This enzyme catalyses the reaction of glycerol and ATP
to give glycerol-3-phosphate and ADP. Analysis of the GK/IIIGlc
complex (PDB codes 1gla and 1glb) revealed that the phosphoryla-
tion site of IIIGlc, His90, is buried in the interface between the two
proteins. This suggested that, phosphorylation of His90 might pre-
vent formation of the GK/IIIGlc complex, leaving the GK free to get
on with its function [16].
5. Allosteric regulation by phosphorylation
Perhaps the most subtle allosteric trigger is the phosphorylation
of a residue far from an active site. A good example is the CheY pro-
tein, a bacterial chemotaxis response regulator which transmits
chemical stimuli to the bacterial ﬂagella and is the end-point of asignal transduction cascade. CheY is activated by histidine kinase
CheA which phosphorylates its Asp57 residue. When phosphory-
lated, CheY binds to the ﬂagellar FliM protein, causing the ﬂagella
to turn clockwise and the bacteria to swim in a tumbling manner.
Unphosphorylated CheY does not readily bind to FliM, causing the
ﬂagella to switch back to their default anti-clockwise rotation,
resulting in smooth swimming. The residue responsible for trigger-
ing clockwise turning is Tyr106, which lies over 9.5 Å from the
phosphorylated Asp57. In early structural studies of CheY, the allo-
steric mechanism was thought to operate via the highly conserved
Thr87 residue which lies directly between Asp57 and Tyr106. This
mechanism was named the ‘‘Y-T” coupling scheme [17] (PDB code
1djm). Subsequent structures seemed to point instead to a signiﬁ-
cant conformational change in the b4-a4 loop (Ala88 to Lys91)
burying the Tyr106 in the active site (PDB codes 3chy and 1jbe)
[18,19]. Molecular dynamics simulations of CheY tended to sup-
port the latter mechanism, with the role of the conserved Thr87
being thought to stabilize the active conformation of the b4-a4
loop [20].
A more dramatic consequence of single-residue phosphoryla-
tion is exempliﬁed by mammalian glycogen phosphorylase in
which the phosphorylation of Ser14, lying some 45 Å away from
the catalytic site, causes a large-scale rotation through 10 of the
two subunits of the dimer, thus opening up the catalytic site for
business [21].
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The formation or breaking of disulﬁde bonds, distant from the
protein’s active site, can trigger a conformational change which af-
fects the protein’s active site [22]. Hence such disulﬁde bonds can
be termed allosteric.
A ﬁne example is that of botulinum neurotoxin type A (BoNT/A),
shown in Fig. 3. This protein is synthesised in Clostridium botulinum
as a single long chain consisting of a catalytic and a translocation
domain. After translation, the two domains are proteolyzed and
split into two separate chains. However, the domains remain con-
nected by a single disulﬁde bond which keeps the translocation do-
main in place, blocking the active site of the catalytic domain and
keeping it inactive (PDB code 3bta). When this disulﬁde is reduced,
either in the acidic endosome or within the cytosol, the domains
separate and the now-active catalytic domain is released into the
cytoplasm [23].
A different use of regulatory disulﬁdes is made by gelsolin, a
protein involved in actin ﬁlament assembly and disassembly. It
binds to actin, severing and capping the actin ﬁlaments before
nucleating a new ﬁlament by binding actin monomers. One factor
affecting its activity is the binding of Ca2+ to its C-terminal domain.
This activates the protein’s functional N-terminal half. Another fac-
tor is a disulﬁde bond in the protein’s second domain [24]. If the
bond is absent, the rate at which Ca2+ activates gelsolin is reduced
(PDB code 1kcq). If the bond is present, Ca2+-mediated activity is
increased. The presence or absence of the bond is determined by
the redox potential of the local environment; the bond tends to
be present when the protein is in plasma, but not when it is in
the cytoplasm [25].
A recent analysis of several proteins known to contain allosteric
disulﬁdes showed that the disulﬁdes all had one thing in common:
they tended to fall into the same conformational class, the –RHSta-
ple bond [26]. This class has a high potential energy, meaning that
the bonds are more easily cleaved than other types. This observa-Fig. 3. An example of an allosteric disulﬁde bond. The diagram shows the secondary st
botulinum (PDB code 3bta). The full-length chain of the protein is cleaved by proteolysis af
single disulﬁde bond (yellow). The active site of the catalytic domain (shown in red) is
cytosol and the catalytic domain is released into the cytoplasm. (a) View of the whole
together.tion provides the possibility of predicting which disulﬁdes might
be allosteric.
7. Allosteric regulation by changes in protein ﬂexibility
In some cases, structural studies have not been able to identify
how the allosteric mechanism operates because there is no, or very
little, conformational difference between the structures of the ac-
tive and inactive forms. One such example is dihydrodipicolinate
synthase (DHDPS) which catalyses the condensation of aspartate-
b-semialdehyde and pyruvate to give 4-hydroxy-2,3,4,5-tetrahy-
dro-2-dipicolinic acid. It is the ﬁrst reaction in the biosynthesis
of lysine in bacteria and plants. The activity of the enzyme is allos-
terically inhibited by lysine, the end product of the pathway. Struc-
tural studies of DHDPS from E. coli were unable to reveal how this
inhibition operates. Neither tertiary nor the homo-tetrameric qua-
ternary structures of the protein differed very much between the
apo- and holo-conformations. The ﬁrst study (PDB codes 1yxc
and 1yxd) [27] suggested a decreased ﬂexibility for an arginine
side chain involved in substrate binding whereas the second study
(PDB code 1dhp) found the opposite effect [28].
One explanation that has been advanced for cases such as this is
that the allosteric effect is not always mediated by a conforma-
tional change. Or at least, not by one that can be detected by stan-
dard X-ray and NMR techniques which give a time-averaged
snapshot of the 3D structure. In some cases, the allosteric signal
may be relayed by an alteration to the dynamic behavior of the
protein. After all, proteins are not static, solid entities but rather
dynamic things, constantly vibrating and constantly in motion.
Their low-frequency modes of vibration are determined by their
shape and mass distribution so, any perturbation, such as the bind-
ing of an allosteric ligand, may affect distant sites via a change in
the spectrum of vibrational frequencies [29–31].
One case where this effect has been experimentally tested is in
PDZ domains. These are among the commonest of protein domainsructure representation of botulinum neurotoxin type A (BoNT/A) from Clostridium
ter translation, but the two parts (shown here in red and blue) are held together by a
blocked by the other chain (blue) until the disulﬁde is reduced in the endosome or
structure and (b) a blow-up of the disulﬁde bond keeping the two chains tethered
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ing domains that recognize the C-terminal 4–6 residues of their
target protein and are involved in protein targeting and protein
complex assembly [32]. The signal, indicating successful recogni-
tion of the target, appears to travel a long distance through these
domains via networks of physically linked ‘‘hot spot” residues,
which can be identiﬁed by statistical analysis of sequence families
[33]. How this signal is propagated was experimentally investi-
gated using side chain (2H-methyl) and backbone (15N) NMR spin
relaxation methods to probe the dynamics of the second PDZ do-
main from human tyrosine phosphatase 1E (hPTP1E) [34]. By com-
paring the differences in dynamics between the apo-form and a
holo-form (containing a C-terminal peptide from the cognate-bind-
ing protein) signiﬁcant differences were detected in the domain’s
ps–ns dynamics, thus providing a possible mechanism for propa-
gating long-range signals within the protein.
A second example is provided by use of NMR and isothermal
titration calorimetry to study the role of dynamics in the allosteric
binding of cAMP to the catabolite activator protein (CAP) [35]. The
authors were able to ‘freeze’ binding conformations at intermedi-
ate stages of cAMP binding and so show that, in this case at least,
the allosteric effect could be explained purely by changes in pro-
tein dynamics.
8. Allosteric regulation by population shift
Another mechanism that has been posited both for explaining
the difﬁcult cases where there is no obvious conformational
change, and as a general explanation of allosteric control, is that
of ‘‘population shift”. This has sometimes been termed the ‘‘new”
view of protein allostery.
Proteins, because of their ﬂexibility and internal motions and
vibrations, exist in a complex statistical ensemble of conformers;
many even contain intrinsically disordered domains [36] which
are often associated with regulatory proteins [37]. Allosteric mech-
anisms may operate by causing a shift of the protein to a different
ensemble of conformations and this change may not be observable
in an experimentally determined 3D structure [38–40]. A similar
explanation has been put forward for enzyme catalysis [41–43].
The CheY example described above, illustrating allosteric control
by phosphorylation, has been used as a test case for molecular
dynamics simulations to see whether the mechanism can be better
explained by traditional ideas of conformational change, or more
recent ideas of change in molecular populations [20]. The authors
probed the protein’s structural, energetic and dynamic properties
as a function of its phosphorylation state and found that neither
the ‘‘new” nor the ‘‘old” explanations of the allosteric mechanism
were complete; a full explanation requires consideration of both
the sequential local structural changes and the concerted collective
motions of the ensemble.
9. Structural surveys
There are many allosteric proteins whose 3D structure has been
determined and allosteric mechanism elucidated. Surprisingly,
there have been few systematic analyses of all these many individ-
ual cases and no proper database where the details of the mecha-
nisms are recorded. Extracting the information from the literature
makes this an arduous task. Perhaps the ﬁrst broad study was that
performed by Daily and Gray [44]. They analyzed a data set of 51
pairs of known active and inactive allosteric protein structures in
the PDB, including enzymes, signalling proteins and DNA-binding
proteins. They compared each pair of structures to identify any lo-
cal conformational differences between them. They found that the
conformations of about 20% of the residues exhibited substantialchanges, with most of the motion in weakly constrained regions
of the structure, such as loops and surface residues. Allosteric bind-
ing resulted in motions in residues over distances that averaged
10–20 Å. Now, although the authors found that non-allosteric pro-
teins also exhibited conformational adjustment on ligand binding,
this was, on average, about half that of the allosteric proteins.
In a second study, the same group looked at the ‘‘coupled net-
works” of contacting residues and their rearrangement in the
structures of 15 pairs of active and inactive allosteric proteins
[45]. They were able to show that in 5 of these, the allosteric signal
is communicated from the allosteric to the active site via changes
in the network of residue-residue contacts between the two sites.
In the remaining 10, the contact networks did not span the two
sites, suggesting some other mechanism, such as large-scale rigid
motions, was at play instead of, or in addition to, the contact
networks.
Using the Daily and Gray data set of 51 structure pairs, the Nus-
sinov group classiﬁed the allosteric mechanisms into three types
according to the magnitude of the conformational change exhib-
ited. The authors suggested the allosteric mechanisms in each
types differed in the relative importance of entropic and enthalpic
effects [46]. The classiﬁcation can be found at http://pro-
tein3d.ncifcrf.gov/tsai/allostery which provides a useful resource
for ﬁnding examples of allosteric effects of varying magnitudes.
10. Summary
Allosteric regulation of protein function is a fascinating and
wide-ranging means of controlling protein function. It encom-
passes a variety of triggers and an assortment of mechanisms for
relaying the signal from the allosteric to the active site. The signal
may be one that activates the protein or inhibits it. Triggers in-
clude: binding of small molecules, binding of proteins, phosphory-
lation and modiﬁcation of disulﬁde bonds. The mechanisms that
these triggers activate can involve the opening or closing of the ac-
tive site, modiﬁcation of the conformation of the residues in the ac-
tive site, changes to the rigidity or electrostatic properties of the
active site, alteration of the dynamic properties of the protein as
a whole or via a population shift in the protein’s conformational
ensemble. Indeed, allosteric effects may involve a combination of
these mechanisms.
Understanding allosteric mechanisms is important in several
ﬁelds. In drug discovery it may provide an alternative means of tar-
geting a protein by small-molecule drugs. The allosteric binding
site may provide a better target than the active site as, being under
less evolutionary pressure, may be more species-speciﬁc [47,48].
One case where this has already been tried is in the structure-
based design of a novel set of p38 map kinase inhibitors that target
the allosteric site [49,50]. Moreover, protein–protein interactions
are notoriously difﬁcult to target with drugs; so, if the interaction
is under allosteric control, targeting the allosteric site might prove
a better bet.
Another area where knowledge of allostery could be useful is in
protein design. Zhang and Bishop [51] describe how they managed
to engineer a novel allosteric site into tyrosine phosphatase (PTP)
using scanning insertional mutagenesis. The new site was regu-
lated by a ﬂuorescin arsenical hairpin binder (FlAsH) and, in one
case, managed to reduce the protein’s activity 12-fold. From exam-
ination of the X-ray structure, the authors deduced the most likely
mechanism by which the inhibition was occurring was the preven-
tion of closure of the PTP’s activation loop.
Finally, the presence of an allosteric site in a newly solved pro-
tein structure might affect the determination of that protein’s func-
tion. It is difﬁcult enough to predict what ligand might bind in a
binding site, so the presence of a second binding site must surely
1698 R.A. Laskowski et al. / FEBS Letters 583 (2009) 1692–1698complicate matters. Perhaps, as we learn more about allosteric sys-
tems it may become possible to develop algorithms to distinguish
allosteric from active sites, and to design novel triggers to inhibit or
activate proteins as required.
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